FASEB J. Mp Biomedicals
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
17/12/1762
02-1102fjev1    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Forbes, J. M.
Right arrow Articles by Cooper, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Forbes, J. M.
Right arrow Articles by Cooper, M. E.
The FASEB Journal Express Article doi:10.1096/fj.02-1102fje
Published online July 18, 2003

The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes

Josephine M. Forbes, Vicki Thallas, Merlin C. Thomas, Hank W. Founds, Wendy C. Burns, George Jerums, and Mark E. Cooper

E-mail contact: Josephine.forbes{at}baker.edu.au

Renal accumulation of advanced glycation end products (AGEs) has been linked to the progression of diabetic nephropathy. Cleavage of pre-formed AGEs within the kidney by a cross-link breaker, such as ALT-711, may confer renoprotection in diabetes. STZ diabetic rats were randomized into a) no treatment (D); b) treatment with the AGE cross-link breaker, ALT-711, weeks 16–32 (DALT early); and c) ALT-711, weeks 24–32 (DALT late). Treatment with ALT-711 resulted in a significant reduction in diabetes-induced serum and renal AGE peptide fluorescence, associated with decreases in renal carboxymethyllysine and RAGE immunostaining. Cross-linking of tail tendon collagen seen in diabetic groups was attenuated only by 16 weeks of ALT-711 treatment. ALT-711, independent of treatment duration, retarded albumin excretion rate (AER), reduced blood pressure, and renal hypertrophy. It also reduced diabetes-induced increases in gene expression of transforming growth factor β1 (TGF-β1), connective tissue growth factor (CTGF), and collagen IV. However, glomerulosclerotic index, tubulointerstitial area, total renal collagen, nitrotyrosine, protein expression of collagen IV, and TGF-β1 only showed improvement with early ALT treatment alone. This study demonstrates the utility of a cross-link breaker as a treatment for diabetic nephropathy and describes effects not only on renal AGEs but on putative mediators of renal injury, such as prosclerotic cytokines and oxidative stress.

Key words: diabetic nephropathy • advanced glycation • cross-link breaker • extracellular matrix • ALT-711




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
A. L. Y. Tan, K. C. Sourris, B. E. Harcourt, V. Thallas-Bonke, S. Penfold, S. Andrikopoulos, M. C. Thomas, R. C. O'Brien, A. Bierhaus, M. E. Cooper, et al.
Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy
Am J Physiol Renal Physiol, March 1, 2010; 298(3): F763 - F770.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
V. R. Drel, W. Xu, J. Zhang, I. A. Pavlov, H. Shevalye, B. Slusher, and I. G. Obrosova
Poly(Adenosine 5'-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy
Endocrinology, December 1, 2009; 150(12): 5273 - 5283.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. T. Coughlan, D. R. Thorburn, S. A. Penfold, A. Laskowski, B. E. Harcourt, K. C. Sourris, A. L.Y. Tan, K. Fukami, V. Thallas-Bonke, P. P. Nawroth, et al.
RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 742 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
M. A. Queisser, F. M. Kouri, M. Konigshoff, M. Wygrecka, U. Schubert, O. Eickelberg, and K. T. Preissner
Loss of RAGE in Pulmonary Fibrosis: Molecular Relations to Functional Changes in Pulmonary Cell Types
Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 337 - 345.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S.-Y. Goh and M. E. Cooper
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1143 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Tikellis, K. Bialkowski, J. Pete, K. Sheehy, Q. Su, C. Johnston, M. E. Cooper, and M. C. Thomas
ACE2 Deficiency Modifies Renoprotection Afforded by ACE Inhibition in Experimental Diabetes
Diabetes, April 1, 2008; 57(4): 1018 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. Thallas-Bonke, S. R. Thorpe, M. T. Coughlan, K. Fukami, F. Y.T. Yap, K. C. Sourris, S. A. Penfold, L. A. Bach, M. E. Cooper, and J. M. Forbes
Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-{alpha}-Dependent Pathway
Diabetes, February 1, 2008; 57(2): 460 - 469.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. T. Coughlan, V. Thallas-Bonke, J. Pete, D. M. Long, A. Gasser, D. C. K. Tong, M. Arnstein, S. R. Thorpe, M. E. Cooper, and J. M. Forbes
Combination Therapy with the Advanced Glycation End Product Cross-Link Breaker, Alagebrium, and Angiotensin Converting Enzyme Inhibitors in Diabetes: Synergy or Redundancy?
Endocrinology, February 1, 2007; 148(2): 886 - 895.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
J. Uribarri and K. R. Tuttle
Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1293 - 1299.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. C. Burns, S. M. Twigg, J. M. Forbes, J. Pete, C. Tikellis, V. Thallas-Bonke, M. C. Thomas, M. E. Cooper, and P. Kantharidis
Connective Tissue Growth Factor Plays an Important Role in Advanced Glycation End Product-Induced Tubular Epithelial-to-Mesenchymal Transition: Implications for Diabetic Renal Disease
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2484 - 2494.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. G. Huebschmann, J. G. Regensteiner, H. Vlassara, and J. E.B. Reusch
Diabetes and Advanced Glycoxidation End Products.
Diabetes Care, June 1, 2006; 29(6): 1420 - 1432.
[Full Text] [PDF]

Home page
 DiabetesHome page
K. Susztak, A. C. Raff, M. Schiffer, and E. P. Bottinger
Glucose-Induced Reactive Oxygen Species Cause Apoptosis of Podocytes and Podocyte Depletion at the Onset of Diabetic Nephropathy
Diabetes, January 1, 2006; 55(1): 225 - 233.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Meerwaldt, J. W.L. Hartog, R. Graaff, R. J. Huisman, T. P. Links, N. C. den Hollander, S. R. Thorpe, J. W. Baynes, G. Navis, R. O.B. Gans, et al.
Skin Autofluorescence, a Measure of Cumulative Metabolic Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis Patients
J. Am. Soc. Nephrol., December 1, 2005; 16(12): 3687 - 3693.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Genuth, W. Sun, P. Cleary, D. R. Sell, W. Dahms, J. Malone, W. Sivitz, V. M. Monnier, and for the DCCT Skin Collagen Ancillary Study Group
Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes
Diabetes, November 1, 2005; 54(11): 3103 - 3111.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
J. M. Bohlender, S. Franke, G. Stein, and G. Wolf
Advanced glycation end products and the kidney
Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. M. Forbes, S. R. Thorpe, V. Thallas-Bonke, J. Pete, M. C. Thomas, E. R. Deemer, S. Bassal, A. El-Osta, D. M. Long, S. Panagiotopoulos, et al.
Modulation of Soluble Receptor for Advanced Glycation End Products by Angiotensin-Converting Enzyme-1 Inhibition in Diabetic Nephropathy
J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2363 - 2372.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. G. Rosca, T. G. Mustata, M. T. Kinter, A. M. Ozdemir, T. S. Kern, L. I. Szweda, M. Brownlee, V. M. Monnier, and M. F. Weiss
Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation
Am J Physiol Renal Physiol, August 1, 2005; 289(2): F420 - F430.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. P. Schena and L. Gesualdo
Pathogenetic Mechanisms of Diabetic Nephropathy
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S30 - S33.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
Diabetes Care, January 1, 2005; 28(1): 164 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Zhou, C. Li, and L. Cai
Advanced Glycation End-Products Induce Connective Tissue Growth Factor-Mediated Renal Fibrosis Predominantly through Transforming Growth Factor {beta}-Independent Pathway
Am. J. Pathol., December 1, 2004; 165(6): 2033 - 2043.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Lassila, K. K. Seah, T. J. Allen, V. Thallas, M. C. Thomas, R. Candido, W. C. Burns, J. M. Forbes, A. C. Calkin, M. E. Cooper, et al.
Accelerated Nephropathy in Diabetic Apolipoprotein E-Knockout Mouse: Role of Advanced Glycation End Products
J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2125 - 2138.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. M. Forbes, L. T. L. Yee, V. Thallas, M. Lassila, R. Candido, K. A. Jandeleit-Dahm, M. C. Thomas, W. C. Burns, E. K. Deemer, S. R. Thorpe, et al.
Advanced Glycation End Product Interventions Reduce Diabetes-Accelerated Atherosclerosis
Diabetes, July 1, 2004; 53(7): 1813 - 1823.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Diabetes Complications
Diabetes Care, June 1, 2004; 27(6): 1506 - 1514.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2003 by The Federation of American Societies for Experimental Biology.